1 completed, 1 not yet recruiting, 1 unknown. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
Follow Bladder Neoplasm: new trials by email Literature Review of Bladder Neoplasm trials Research Report on Bladder Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer Sacituzumab Govitecan + Zimberelimab - Bladder Cancer, Bladder Urothelial Carcinoma | Phase 2 | Not yet recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 63 | 2024-12-02 | 2024-07-30 |
| En-Bloc Resection of Bladder Tumors En Bloc Resection, Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar) - Bladder Neoplasm | Phase 2 | Unknown | Betul Kartal | 60 | 2020-04-01 | 2022-04-12 |
| Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder Pralatrexate Injection, Vitamin B12, Folic Acid - Carcinoma, Transitional Cell, Bladder Cancer | Phase 2 | Completed | Acrotech Biopharma Inc. | 30 | 2008-07-01 | 2019-12-17 |
Urinary Bladder Neoplasms (3) · Carcinoma (1) · Carcinoma, Transitional Cell (1) · Neoplasm Metastasis (1) · Recurrence (1) · Urogenital Neoplasms (1) · Urologic Neoplasms (1)
Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Male Urogenital Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Urinary Bladder Diseases (3) · Urogenital Diseases (3) · Urologic Diseases (3) · Urogenital Neoplasms (2) · Urologic Neoplasms (2) · Disease Attributes (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Neoplastic Processes (1) · Pathologic Processes (1)
10-propargyl-10-deazaaminopterin (1) · Folic Acid (1) · Vitamin B 12 (1) · sacituzumab govitecan (1) · zimberelimab (1)
Acrotech Biopharma Inc. (1) · Betul Kartal (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1)
Argentina (1) · Belgium (1) · Croatia (1) · France (1) · Italy (1) · Spain (1) · Turkey (Türkiye) (1) · United States (1)
Garry Weems, Pharm.D. (1) · Giuseppe Procopio, MD (1)